https://doi.org/10.5281/zenodo.15826866

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

Computer Aided Drug Development

ISBN Number- 978-81-985724-6-2

Chapter- 4



Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

COMPUTER-AIDED BIOPHARMACEUTICAL CHARACTERIZATION (IN VITRO–IN VIVO CORRELATION

V. GEETHA
Lecturer in Chemistry, Government Degree College,
RCPM, AP Pin -533255
velalamgeetha@gmail.com

DR. MONIKA RAKSE
Assistant Professor
LCIT School of Pharmacy, Bilaspur
Pin- 495001
Email: monika.rakse09@gmail.com

MS. SNNEHAA BHOSLE
Assistant Professor
TMV'S Lokmanya Tilak Institute of Pharmaceutical Sciences Pune
Pin 411037
Email: shivank.sneha853@gmail.com

MONU KUMAR (MK GROVER)
Associate Professor
Doon valley Institute of Pharmacy & medicine karnal
Pin: 132001
Email: mkgrovers527@gmail.com

NEHA ARORA
Associate Professor
Suresh Gyan Vihar University, Jagatpura, Jaipur
Pin: 302017
Email: arora.neha312@gmail.com

https://doi.org/10.5281/zenodo.15826866

Chapter IV…

COMPUTER-AIDED BIOPHARMACEUTICAL CHARACTERIZATION (IN VITRO–IN VIVO CORRELATION)

V. GEETHA
Lecturer in Chemistry, Government Degree College,
RCPM, AP Pin -533255

DR. MONIKA RAKSE
Assistant Professor
LCIT School of Pharmacy, Bilaspur
Pin- 495001
Email: monika.rakse09@gmail.com

MS. SNNEHAA BHOSLE
Assistant Professor
TMV'S Lokmanya Tilak Institute of Pharmaceutical Sciences Pune
Pin 411037
Email: shivank.sneha853@gmail.com

MONU KUMAR (MK GROVER)
Associate Professor
Doon valley Institute of Pharmacy & medicine karnal
Pin: 132001
Email: mkgrovers527@gmail.com

NEHA ARORA
Associate Professor
Suresh Gyan Vihar University, Jagatpura, Jaipur
Pin: 302017
Email: arora.neha312@gmail.com

https://doi.org/10.5281/zenodo.15826866

The idea of in vitro–in vivo correlation (IVIVC) is essential to comprehending the connection between the therapeutic benefits felt in the human body (in vivo) and the drug release properties seen in laboratory testing (in vitro). By providing vital information about the bioavailability and effectiveness of medication formulations, this correlation aids in bridging the gap between laboratory research and clinical results. To increase drug development efficiency and guarantee consistent therapeutic effects, researchers can use modelling and simulation approaches to predict and optimise the in vivo drug behaviour based on in vitro data. Because it makes it possible to create more dependable and efficient pharmacological formulations, IVIVC is particularly useful in the development of dosage forms. Numerous sophisticated software tools are available to help with IVIVC prediction and optimisation. These tools give researchers the computational capacity to model intricate biological processes and improve formulations prior to clinical trials, ultimately improving the safety and effectiveness of novel drugs.

4.1. UNDERSTANDING THE BASICS OF IN VITRO–IN VIVO CORRELATION (IVIVC)

A predictive mathematical model called In Vitro–In Vivo Correlation (IVIVC) links a drug's in vivo pharmacokinetic performance (such plasma drug concentration or bioavailability) to its in vitro properties (usually its dissolution or release behaviour) [1]. Because it helps predict how a drug will behave in the human body based on laboratory data, IVIVC is essential to drug development, especially for oral dose formulations. In order to enable biowaivers, minimise the need for lengthy human studies during formulation modifications, and guarantee constant therapeutic performance, the U.S. FDA and other international regulatory agencies acknowledge IVIVC as a useful tool. IVIVC is divided into three levels, each of which offers a distinct degree of predictability and application scope: Level A (point-to-point correlation), Level B (statistical moment analysis), and Level C (single-point correlation). Because Level A IVIVC can correctly model plasma concentration profiles, it is the most informative and recommended for regulatory submissions. The drug's physicochemical characteristics, formulation design, gastrointestinal physiology, and the reliability of in vitro dissolution testing techniques are some of the variables that can affect the establishment and precision of IVIVC. Utilising IVIVC to optimise drug formulations and expedite their regulatory approval process requires an understanding of these fundamental components.



Figure 1: IVIVC

4.1.1 Definition and Importance of IVIVC

Essentially a predictive mathematical model, the In Vitro–In Vivo Correlation (IVIVC) establishes a connection between an in vivo response, like plasma drug concentration, and an in vitro drug attribute, such the rate of dissolution [2]. It links formulation behaviour in controlled settings to the drug's therapeutic efficacy in real-world situations by serving as a scientific link between laboratory-based testing and the drug's actual biological performance inside the human body. Based on a medication's performance in in vitro experiments, IVIVC is a useful method for forecasting drug release and absorption, assisting formulators in anticipating how a drug would act once administered. IVIVC is a fundamental component of logical drug development and formulation optimisation because of its predictive power.

Here Are the Below Given Importance

1. **Reduces Need for Human Studies:** Reducing the dependence on human clinical trials is one of the most significant benefits of using a verified In Vitro–In Vivo Correlation (IVIVC). A validated IVIVC model enables pharmaceutical developers to forecast a drug's in vivo behaviour based only on in vitro dissolution data, particularly during the

different stages of formulation adjustments. The necessity for carrying out numerous, frequently costly bioequivalence tests is eliminated by this predictive capability. In addition to speeding up the medication development process, this also resolves moral dilemmas raised by repeatedly exposing human volunteers to clinical studies. In the end, IVIVC saves important resources while facilitating the shift from laboratory-based research to clinical application.

2. **Supports Regulatory Submissions:** In order to facilitate regulatory submissions and approvals, IVIVC plays a key role. IVIVC is acknowledged by regulatory bodies like the U.S. Food and Drug Administration (FDA) as a scientifically sound method for defending exemptions for in vivo bioequivalence studies, particularly when it comes to post-approval modifications to medication formulations. This implies that pharmaceutical companies can make formulation changes without doing further clinical investigations after an IVIVC has been validated, saving money and time while maintaining product quality. IVIVC is a crucial tool in regulatory science since it makes it easier to get biowaivers, streamlines regulatory paperwork, and speeds up the release of updated formulations.
3. **Enhances Formulation Development:** Contributing to the creation and improvement of medication formulations, especially for controlled-release and modified-release medications, is another significant advantage of IVIVC. IVIVC provides important information on how a medicine acts inside the body by comparing the rate of in vitro drug release with the rate of in vivo drug absorption. This eliminates the need for extensive testing on humans or animals by enabling pharmaceutical experts to predict the therapeutic outcomes and modify formulation parameters in a lab setting. Drug formulation efficiency and innovation are improved by the capacity to model and assess drug behaviour under controlled circumstances, resulting in more potent and patient-friendly pharmaceutical products.
4. **Improves Quality Control:** The ability to employ in vitro dissolution tests as trustworthy stand-ins for in vivo performance makes IVIVC an invaluable quality control tool as well. The establishment of a robust IVIVC facilitates the monitoring and management of batch-to-batch consistency throughout the production process. Before the product reaches the patient, any divergence in in vitro dissolution rates can be detected early and corrected in a timely manner. Predictive monitoring guarantees the efficacy of treatments and enhances product dependability. Additionally, adding

IVIVC to quality control procedures helps ensure that high-quality pharmaceutical products are consistently delivered and reinforces adherence to legal requirements.

5. **Cost-Effective and Time-Saving:** A novel drug's development and commercialisation are difficult, resource-intensive processes that usually require several clinical studies, each of which raises the final cost and timetable. IVIVC uses predictive models derived from in vitro data to offer a more affordable option. By drastically lowering the number of clinical trials needed, these models help speed up product development and save costs. The ability to employ IVIVC to avoid repeated studies becomes a significant competitive advantage in an industry where a product's time to market might decide its success or failure. As a result, IVIVC expedites patient access to novel and enhanced treatments while also saving time and money.

4.1.2 Classification of IVIVC Levels (A, B, C)

The three levels of the In Vitro–In Vivo Correlation (IVIVC) framework—Level A, Level B, and Level C—are determined by the type of relationship and degree of correlation found between in vitro drug release and in vivo absorption. Level A is the most complete and legally recognised type of IVIVC, whereas each level offers differing degrees of predictability. Each level is described in detail below [3]:

Level A IVIVC – Point-to-Point Correlation

The most dependable and instructive level of In Vitro–In Vivo Correlation (IVIVC) is Level A. Usually expressed as plasma drug concentration or the total amount of drug absorbed over time, it shows a clear, point-to-point relationship between a drug's whole in vitro dissolution profile and its in vivo input rate. As the most complete model, this degree of correlation offers a linear and predictive relationship between the drug release in the lab and the real absorption process that takes place in the human body. Level A's point-to-point methodology guarantees that the complete release profile is taken into consideration, providing a high degree of predictability regarding the pharmacokinetic behaviour of the medication.

Extended-release (ER) and modified-release formulations benefit greatly from Level A IVIVC since it helps guarantee the formulation's therapeutic equivalency to the reference product. It is generally accepted by regulatory agencies like the FDA, which frequently approves biowaivers for changed formulations when a Level A link has been verified. This implies that

https://doi.org/10.5281/zenodo.15826866

the pharmaceutical corporation may, in some circumstances, modify the drug formulation after approval (for example, by altering the manufacturing method or excipients) without engaging in further in vivo clinical research. The plasma drug profile should reflect the original product's dissolution profile as long as the new formulation exhibits the same one, guaranteeing patients consistent therapeutic results [4].

Furthermore, a Level A IVIVC can greatly improve the effectiveness of the drug development process after it has been verified. Without having to pay for or wait for more bioequivalence tests, manufacturers can move on with formulation adjustments, production scaling, or other changes with confidence. The pharmaceutical firm and the patients who depend on the drug's therapeutic efficacy eventually gain from Level A IVIVC's predictive power, which not only speeds time-to-market but also guarantees consistent quality control across batches and regulatory compliance.

Level B IVIVC – Statistical Moment Analysis

Level B IVIVC uses statistical moment analysis, frequently concentrating on metrics like mean dissolution time (MDT) and mean residence time (MRT), to build a connection between the in vitro dissolution profile and the in vivo pharmacokinetic data. Level B does not give a direct, linear relationship between each individual data point of the in vitro and in vivo curves, in contrast to Level A, which offers a point-to-point correlation. Rather, it offers a correlation based on summary statistical descriptors that are obtained from the profiles of absorption and dissolution. This method lacks the accuracy of a point-by-point match but can capture the overall behaviour of the medication by using the overall shapes and patterns of the curves to create a single correlation point.

The predictive power of Level B for the drug formulation development process is limited by its dependence on statistical moments like MDT and MRT, despite the fact that it includes all of the data points from the in vitro and in vivo profiles. This is because it is less accurate at forecasting certain pharmacokinetic outcomes because it does not give the comprehensive relationship between the dissolution and absorption at each step of the process. Therefore, it cannot as confidently ensure therapeutic equivalency as Level A IVIVC, even if it can provide a broad picture of how the drug may behave in the body. As a result, the model's use in improving medication compositions or forecasting the results of changes is restricted.

https://doi.org/10.5281/zenodo.15826866

Level B IVIVC is typically not accepted for regulatory decision-making pertaining to bioequivalence waivers or significant formulation changes because of these restrictions. When deciding whether to approve, modify, or waive a product, regulatory bodies like the FDA favour more thorough and predictive models like Level A. Level B's role in the regulatory approval process is limited because it is much less able to enable formulation adjustments or post-approved alterations in the absence of a clear point-to-point correlation. But even in the early phases of formulation development or when additional specific data is not yet available, it can nevertheless offer insightful information about broad patterns and behaviours [5].

Level C IVIVC – Single-Point Correlation

The most fundamental and straightforward type of in vitro–in vivo correlation is Level C IVIVC. It creates a connection between a single pharmacokinetic parameter, like C_max (the maximum plasma concentration) or AUC (area under the plasma concentration-time curve), and a single point on the in vitro dissolution curve, like the percentage of drug dissolved at a given time, like one hour. This correlation cannot provide the comprehensive, predictive insights that are possible with Level A or Level B correlations since it only offers a crude estimate of the in vivo behaviour based on sparse data. Because Level C is so basic, it is not comprehensive enough to provide more accurate predictions about how a medication formulation will behave in the body over time.

Level C alone is not enough to secure regulatory approvals, even though it can be a helpful tool in the early phases of formulation development, especially when screening and choosing potential formulations. Because Level C does not offer a strong enough connection between the drug's overall in vivo pharmacokinetic behaviour and its in vitro dissolution profile, regulatory bodies such as the FDA generally do not accept it as the exclusive basis for decisions pertaining to bioequivalence or formulation modifications. Level C, however, can be useful in preliminary formulation evaluations, particularly when researchers are attempting to rapidly determine whether formulations may be able to satisfy performance requirements.

To create a more complete picture of the dissolution profile and its connection to the pharmacokinetic results, Level C correlations may occasionally be accepted in combination with several additional Level C correlations at different times. Furthermore, Level C correlations could serve as initial data that is backed up by more clinical and pharmacokinetic research. This method can improve overall predictive power and offer a more solid foundation

https://doi.org/10.5281/zenodo.15826866

for choosing formulations. Even with its drawbacks, Level C IVIVC is nevertheless useful in the early stages of formulation since it provides rapid information about a drug's possible performance based on little in vitro evidence [6].

4.1.3 Regulatory Perspectives on IVIVC

In order to make sure that a medication product's performance in the body matches its performance in laboratory testing, the pharmaceutical industry relies heavily on in vitro–in vivo correlation, or IVIVC. Specific recommendations for the use of IVIVC in the drug approval process have been developed by regulatory authorities, including the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and other international regulatory bodies. These organisations acknowledge that IVIVC plays a significant role in assisting with bioequivalence assessments and post-approval adjustments to medication formulations.

From a regulatory standpoint, IVIVC provides a way to forecast a drug's physiological behaviour based on laboratory observations, acting as a scientific link between in vitro dissolution testing and in vivo pharmacokinetic data. In order to support the waiver of in vivo bioequivalence studies, regulatory bodies support the use of IVIVC for biowaivers. This is especially helpful when formulations differ in certain formulation features, including medication release rates, but share a similar composition with an approved reference product. Pharmaceutical businesses can speed up the time to market for new formulations or generics by exhibiting a strong IVIVC connection, which will prevent them from having to conduct expensive and time-consuming clinical trials [7].

Level A IVIVC is typically regarded as the gold standard for regulatory applications by the FDA and other organisations. Without requiring further clinical research, a validated Level A IVIVC can support formulation adjustments, scale-up procedures, or even post-approval product alterations. The predictive power is less for Level B and Level C IVIVC, nevertheless, and these correlations are typically not recognised as the only foundation for regulatory decisions, especially when it comes to bioequivalence waivers or significant formulation modifications.

The significance of validation in IVIVC development is emphasised by regulatory organisations. IVIVC requires scientific validation of the connection before it can be approved

for regulatory filings. This usually entails identifying any potential heterogeneity between the two datasets and proving a strong and repeatable link between in vitro dissolution profiles and in vivo pharmacokinetic data. To make sure the medication has the desired therapeutic benefits, regulators will assess if the IVIVC model makes accurate predictions that match clinical performance [8].

Furthermore, regulatory viewpoints emphasise that there is no one-size-fits-all strategy for IVIVC. Its application varies by medication kind, formulation, and degree of correlation attained and is very context-dependent. IVIVC, for instance, is very beneficial for controlled-release formulations and modified-release dose forms, while immediate-release formulations might not need such a thorough examination. As a result, IVIVC's regulatory environment is constantly changing, with new requirements being added to match developments in science and technology in the pharmaceutical sector.

By providing bioequivalence exemptions, lowering the requirement for in vivo investigations, and streamlining regulatory submissions for formulation modifications, IVIVC plays a crucial role in medication development and regulation. In order to guarantee that medications function efficiently and reliably, boosting therapeutic results and streamlining the drug approval process, its adoption and validation are essential.

4.1.4 Factors Influencing IVIVC

- **Drug Properties**: The strength of the IVIVC is mostly determined by the intrinsic characteristics of the medication, including its solubility, permeability, and rate of dissolution. The relationships between in vitro dissolution and in vivo absorption may be poorer for medications with variable permeability or poor solubility. For example, there may be notable differences between laboratory testing and real absorption in the body for medications that are very lipophilic or have sluggish rates of disintegration. These elements may degrade the IVIVC by reducing the accuracy of in vivo performance predictions. Conversely, medications with predictable absorption profiles and high solubility typically exhibit more stable IVIVC correlations.
- **Formulation Factors**: IVIVC is greatly influenced by the drug formulation's design and chemistry. The rate and degree of medication dissolution can be changed by variations in excipients, including binders, fillers, lubricants, and disintegrants. Additionally, the drug's pharmacokinetic profile and release kinetics may be impacted

by the dosage form itself, including sustained-release formulations, immediate-release tablets, and modified-release systems. For example, because the in vitro dissolution rate must to closely resemble the drug's release profile in the body over a prolonged period of time, sustained-release formulations frequently call for a more sophisticated IVIVC.

- **In Vitro Testing Conditions**: The strength of IVIVC may be affected by the circumstances surrounding in vitro dissolution testing. Drug release patterns can vary depending on a number of factors, including temperature, pH, dissolve media, and the speed at which the mixture is stirred throughout the dissolution test. The capacity of in vitro data to forecast the behaviour of drugs in vivo may be impacted by these disparities. For instance, the results of the dissolution test could not be a trustworthy representation of the drug's in vivo effectiveness if it fails to accurately replicate the conditions of the gastrointestinal tract, such as the presence of food or the fluctuating pH levels.
- **Biopharmaceutical Factors**: One important aspect affecting IVIVC is the gastrointestinal (GI) environment. Numerous factors, including intestinal motility, gastric emptying time, and the presence of food in the stomach, influence the rate and degree of medication absorption. The way a medicine is absorbed following oral delivery can vary significantly depending on certain biological factors. To guarantee a precise forecast, the IVIVC model needs to take these factors into consideration. For instance, certain modifications to the in vitro testing conditions may be necessary for medications that rely heavily on the pH or enzymes of the stomach for absorption in order to account for the fluctuations in the GI environment.
- **Modeling and Analytical Techniques**: The strength of IVIVC is also greatly influenced by the statistical techniques and mathematical models that were employed to evaluate the data. The degree of connection between in vitro and in vivo data might vary depending on the type of model used, including statistical moment analysis, empirical models, and mechanistic models. The predictive capability of the IVIVC is affected by the modelling approach selected and the data's correctness. Furthermore, to make sure that the association remains true in practical settings, the validation procedure—which entails contrasting the anticipated in vivo data with clinical observations—is crucial. The IVIVC might not offer trustworthy or useful information

for formulation development or regulatory filings in the absence of strong analytical methods.

4.2 MODELING AND SIMULATION TECHNIQUES FOR IVIVC

Since modelling and simulation techniques offer a systematic framework to predict and comprehend the relationship between in vitro dissolution profiles and in vivo pharmacokinetic responses, they are essential for developing a strong In Vitro–In Vivo Correlation (IVIVC) [9]. These simulations heavily rely on pharmacokinetic (PK) and pharmacodynamic (PD) models, which describe how medications are absorbed, distributed, metabolised, and excreted (ADME) within the body. These models assist in forecasting a drug's post-administration behaviour while accounting for the intricacies of the body's biological functions. The concentration of the medication in the plasma over time is the main focus of pharmacokinetic models, which offer important information about the drug's kinetics of absorption and excretion. Pharmacodynamic models, on the other hand, are used to forecast how a medicine will affect the body, specifically with regard to its potential adverse effects and therapeutic action. These models are crucial for connecting data on in vitro dissolution with pharmacokinetic results in vivo, particularly for complicated formulations like extended-release dosage forms. Furthermore, compartmental models aid in the description of the drug's passage through the various bodily compartments, but non-compartmental models are frequently used to examine the whole drug concentration-time data without presuming a particular compartmental structure.

Statistical moment analysis, mechanistic models, and empirical models are among the mathematical modelling techniques used to further improve the predicted accuracy of IVIVC. Formulators can create and improve drug delivery systems by using these techniques to measure the correlation between the in vivo absorption rate and the in vitro drug release rate. For example, drug movement between the body's various interrelated compartments—such as the gastrointestinal system, circulation, and tissues—is modelled by compartmental models. Non-compartmental models, on the other hand, do not specify individual compartments and instead concentrate on the overall pharmacokinetic data. Since gastrointestinal pH, enzyme activity, and blood flow can all have an impact on a drug's absorption and effectiveness, ADME simulation is essential for forecasting how the drug will behave. Through the integration of pharmacokinetic characteristics and dissolution data, these simulations allow researchers to

https://doi.org/10.5281/zenodo.15826866

optimise dose forms for the best possible therapeutic results [10]. In addition to saving time and money, the integration of mathematical modelling and simulation approaches makes it easier to anticipate clinical performance from preclinical data. This helps with regulatory filings and biowaiver applications.

4.2.1 Role of Pharmacokinetic and Pharmacodynamic Models

The development and validation of In Vitro–In Vivo Correlation (IVIVC) depend heavily on pharmacokinetic (PK) and pharmacodynamic (PD) models, which provide a thorough understanding of how a drug acts in the body and produces its effects. In order to forecast in vivo drug efficacy based on in vitro dissolution data, these models offer critical insights into the absorption, distribution, metabolism, and excretion (ADME) processes of pharmaceuticals [11].

Predicting drug absorption rates, bioavailability, and elimination kinetics is made possible by pharmacokinetic models, which depict the time course of drug concentration in the bloodstream and tissues. These models aid in simulating a drug's post-administration passage through the body, including the pace and degree of absorption, tissue distribution, enzyme metabolism, and eventual excretion. Drug concentration profiles are analysed and predicted using a range of PK models, including compartmental and non-compartmental techniques, which makes it easier to forecast therapeutic results based on in vitro release features. PK models enable the prediction of in vivo performance, particularly for controlled-release formulations, by establishing a correlation between a drug's dissolving profile (for example, from a dissolution test) and plasma drug concentration-time profiles.

On the other hand, pharmacodynamic models are used to forecast how a medicine will affect the body, including any toxicity, side effects, or therapeutic effects. PD models show a connection between a drug's pharmacological activity and its plasma levels. Understanding how drug concentration affects therapeutic responses, such as dose-response relationships, duration of action, and efficacy, requires an understanding of these models. Researchers can forecast how much of the drug will be absorbed, how it will be distributed throughout the body, and how it will have the desired therapeutic effects by combining the PK and PD models [12].

Since they connect the in vitro dissolution data to actual pharmacokinetic results, like plasma drug concentration patterns and therapeutic effects, PK and PD models work together to create

https://doi.org/10.5281/zenodo.15826866

a potent tool for IVIVC. By forecasting the potential effects of formulation modifications on medication absorption and efficacy, these models help optimise drug formulations and enable more precise clinical performance predictions from preclinical data. They also play a crucial role in regulatory submissions, reducing the need for lengthy in vivo clinical investigations and allowing the scientific rationale of biowaivers. In the end, PK and PD models are essential to the creation of new pharmaceutical goods because they guarantee that drug compositions are both safe and effective.

4.2.2 Mathematical Approaches to IVIVC Modeling

In order to connect in vitro drug release data with in vivo pharmacokinetic (PK) results, mathematical methods for In Vitro-In Vivo Correlation (IVIVC) modelling are essential. These methods make sure that medication formulations work as intended by using a range of mathematical tools to forecast how pharmaceuticals will behave in the body [98]. Among the primary mathematical techniques are:

1. **Statistical Moment Analysis**: In vitro dissolution profiles and in vivo absorption data are frequently correlated using statistical moment analysis. Statistical metrics like the mean residency time (MRT) and the mean dissolution time (MDT) are used in the procedure. It is possible to determine the connection between the drug's release and absorption into the body by contrasting these instances from the in vitro and in vivo data. For formulations like Level B IVIVC, where a thorough point-to-point correlation is not feasible, this approach is especially helpful.

2. **Zero-Order and First-Order Kinetic Models**: These models make the assumption that the drug's release occurs according to particular kinetic orders, such as first-order (drug release that declines over time) or zero-order (continuous drug release). In controlled-release formulations when achieving a constant release rate is the aim, zero-order kinetics are frequently employed. On the other hand, when drug release is proportionate to the amount of drug left, first-order kinetics are used. These models aid in forecasting the effects of formulation modifications (such as altering the rate of dissolution) on drug absorption and therapeutic effect.

3. **Empirical Models**: In order to demonstrate correlations between in vitro and in vivo data, empirical models rely on observable experimental data. These models typically

concentrate on fitting the observed data to predetermined mathematical equations rather than requiring a thorough mechanistic knowledge of the drug's release behaviour. These models are frequently employed in real-world scenarios when a strong predictive correlation is required but precise mechanistic insights may not be available.

4. **Compartmental Models**: Compartmental models divide the body into central and peripheral compartments to mimic the distribution and excretion of a medication within the body. A drug's absorption, distribution, metabolism, and excretion over time can all be predicted using these models. It is feasible to forecast plasma concentration profiles and create an IVIVC by fusing compartmental PK models with in vitro release data. This method works especially well for more complicated formulations, such extended-release systems, where a number of variables affect the drug's release.

5. **Numerical Simulations and Optimization**: IVIVC also makes use of sophisticated mathematical modelling methods including optimisation algorithms and numerical simulations. These methods entail resolving differential equations that control the rates of medication absorption and dissolution. These equations' solutions offer a mathematical forecast of how drugs would behave in vivo. The model parameters are then adjusted using optimisation approaches to produce a more precise connection between in vivo pharmacokinetics and in vitro dissolution data.

These mathematical techniques lessen the need for costly and time-consuming clinical trials by enabling researchers to forecast the in vivo efficacy of novel drug formulations based on in vitro dissolving data. They support regulatory submissions and biowaiver requests while aiding in the design and optimisation of medications by precisely simulating drug release and absorption. This ensures consistent therapeutic effects [13].

4.2.3 Compartmental and Non-Compartmental Models

In vitro dissolution profiles and in vivo drug absorption are reliably correlated through the use of compartmental and non-compartmental models, which are the two main methods used in the context of In Vitro-In Vivo Correlation (IVIVC) to predict the drug's pharmacokinetic behaviour following oral administration [14].

https://doi.org/10.5281/zenodo.15826866

Compartmental Models

A classic and popular method in pharmacokinetics for characterising drug absorption, distribution, metabolism, and excretion (ADME) over time is the use of compartmental models. These models depict the body as a collection of interrelated "compartments," each of which represents a distinct physiological area where the medication may be distributed. The compartments usually consist of a core compartment (blood plasma, for example), where the medication is quickly absorbed and removed, and peripheral compartments (tissues and organs), where the drug may build up or be stored [15].

- **Model Structure**: The number of compartments used to depict the drug's pharmacokinetic profile determines whether a compartmental model is one-compartment or multi-compartment. A one-compartment model assumes that the drug will quickly spread uniformly throughout the body, with absorption and disposal processes taking place from this one compartment. Multi-compartment models are more intricate and presume that the medication distributes differently in different tissues and organs, with separate regions being responsible for absorption, distribution, metabolism, and disposal**.**

- **Application in IVIVC**: Predicting the plasma concentration-time curve from in vitro dissolution data is frequently done using compartmental models. These models anticipate the behaviour of drugs after administration by relating the in vivo absorption and distribution properties to the in vitro drug release profile (dissolution rate). The therapeutic efficacy of controlled-release formulations is greatly influenced by drug release rates and absorption kinetics, hence this is very critical.

1. **Non-Compartmental Models**

Non-compartmental models do not make any assumptions about particular physiological compartments, in contrast to compartmental models. Rather, by employing empirical connections to characterise the drug's pharmacokinetic behaviour, these models concentrate on the observed drug concentration in the bloodstream over time. The area under the curve (AUC) concept and other quantifiable pharmacokinetic characteristics, including C_max (the maximum plasma concentration) and T_max (the time at which C_max occurs), are the foundation of non-compartmental techniques.

- **Model Structure**: Assumptions on the number or kind of compartments in the body are not necessary for non-compartmental analysis. Rather, it computes critical pharmacokinetic parameters such as AUC, half-life, elimination rate constant, and mean residence time from observed concentration-time data. The correlations between in vitro dissolution profiles and in vivo pharmacokinetics are then established using these parameters [16].

- **Application in IVIVC**: Non-compartmental models are especially helpful for investigations on bioavailability and first-pass effects, when the emphasis is on the drug's total exposure in the body rather than its precise distribution and removal patterns. When only basic pharmacokinetic information (such AUC and C_max) is available in the early stages of IVIVC development, non-compartmental analysis is frequently employed. It simplifies the IVIVC process when comprehensive compartmental data is not required by establishing a link between in vitro dissolution rates and the total systemic drug exposure.

Table 1: Comparison between Compartmental and Non-Compartmental Models

Aspect	Compartmental Models	Non-Compartmental Models
Complexity	More complex, involving multiple compartments to represent drug distribution, metabolism, and elimination in the body.	Simpler, based on overall systemic drug exposure without assuming specific compartments.
Prediction Accuracy	More accurate for detailed predictions of drug concentration over time across various tissues and compartments.	Provides a less detailed prediction but focuses on overall systemic exposure (AUC, C_max, etc.).
Application	Ideal for sustained-release or extended-release formulations, where complex pharmacokinetics need to be considered.	Suitable for early-stage drug development or when detailed pharmacokinetic data is unavailable.

https://doi.org/10.5281/zenodo.15826866

Data Requirements	Requires extensive data on drug distribution and elimination across various body compartments.	Requires less data, primarily focused on the drug concentration-time profile and basic pharmacokinetic parameters (AUC, C_max).
Usage in IVIVC	Provides detailed pharmacokinetic insights that allow for a more precise in vitro-in vivo correlation, especially in complex formulations.	Offers a simplified correlation between in vitro dissolution and in vivo performance, typically used in early-stage development or with basic pharmacokinetic data.
Advantages	- Detailed insights into pharmacokinetics. - More accurate for complex formulations. - Better for controlled-release formulations.	- Simple and straightforward. - Easier to apply with limited data. - Ideal for early-stage development.
Disadvantages	- More data-intensive. - Requires a higher level of complexity in model construction and data analysis.	- Less detailed, missing information on tissue distribution. - Not suitable for complex formulations or late-stage development.

4.2.4 Simulation of Absorption, Distribution, Metabolism, and Excretion (ADME)

The modelling and forecasting of a drug's in vivo performance heavily relies on the Absorption, Distribution, Metabolism, and Excretion (ADME) simulation. These procedures are essential for figuring out a drug's pharmacokinetic profile, which has a direct impact on both its safety and therapeutic efficacy. ADME models shed light on how a medication acts when it is taken, from when it enters the body to when it is eliminated [17]. An essential part of in vitro–in vivo correlation (IVIVC) is the incorporation of these processes into a comprehensive model, which aids in forecasting a drug's in vivo pharmacokinetics based on in vitro data.

https://doi.org/10.5281/zenodo.15826866

1. Absorption Simulation

The process by which a medication enters the bloodstream following administration is referred to as absorption. Numerous elements, including the drug's formulation, permeability, solubility, and the physiological state of the gastrointestinal tract, might affect this process. Understanding the commencement of pharmacological action requires knowing how quickly the drug is absorbed into the systemic circulation, which can be predicted with the use of absorption simulation. The absorption phase is frequently simulated using models like GastroPlus® and the first-pass metabolism model [18].

2. Distribution Simulation

After absorption, the medication travels through the bloodstream to different parts of the body. Blood flow to tissues, tissue binding affinity, and the medication's capacity to pass across biological barriers—like the blood-brain barrier—all affect how a drug is distributed. To ascertain the drug's therapeutic efficacy in target areas and to minimise toxicity in non-target tissues, simulations of the distribution phase offer valuable insights into how the drug spreads to different organs and tissues. To represent the distribution phase of ADME, physiologically-based pharmacokinetic (PBPK) models are frequently employed.

3. Metabolism Simulation

Metabolism refers to the biotransformation of a drug into its metabolites, typically in the liver. The metabolism of a drug can significantly affect its activity, as metabolites may be either active or inactive. Simulation of metabolism helps predict the drug’s half-life and clearance rate, as well as identify potential metabolites and their pharmacological effects. The **Cytochrome P450 enzyme system** plays a significant role in drug metabolism, and modeling this system can help predict potential drug-drug interactions. Software tools like **SimCYP** are used to simulate the metabolic phase and predict drug interactions and clearance.

4. Excretion Simulation

Excretion is the process by which a drug and its metabolites are removed from the body, usually through urine from the kidneys or, to a lesser degree, through bile and faeces. Excretion simulation aids in determining the overall drug clearance rate and the pace at which the medication is eliminated from the body. This information is crucial for adjusting dosage,

particularly in populations with compromised hepatic or renal function. Excretion simulations, which forecast how long a medication will remain in the body and how effectively it will be removed, also use PBPK models [19].

5. Integration of ADME Simulation in IVIVC

A comprehensive understanding of a drug's pharmacokinetics can be obtained by integrating all of these processes—absorption, distribution, metabolism, and excretion—into a thorough simulation. The foundation of IVIVC is the connection between in vitro drug dissolution data and in vivo therapeutic outcomes, which is made possible by these simulations. Researchers can forecast how formulation modifications (such altering the dissolving rate) would impact the drug's systemic exposure, therapeutic efficacy, and safety by simulating the entire ADME process.

4.3 APPLICATIONS OF IVIVC IN DOSAGE FORM DEVELOPMENT

In Vitro–In Vivo Correlation (IVIVC) is a crucial tool for formula optimisation and clinical outcome prediction in the field of dosage form development. IVIVC is a prediction model that supports the early design phases of pharmaceutical formulations by establishing a correlation between in vitro drug release profiles and in vivo pharmacokinetic data. Optimising controlled-release and sustained-release medication systems is one of the most important uses of IVIVC. Since the therapeutic efficiency of these formulations depends on the ability to sustain a constant concentration of the drug in the bloodstream over a lengthy period of time, exact control over the pace and extent of drug release is necessary [20]. Formulators can adjust dissolution rates and forecast how these modifications will affect actual drug absorption using IVIVC, guaranteeing that the dosage form will produce the intended therapeutic benefits. In order to enhance therapeutic results, the correlation also aids in the creation of formulations that increase bioavailability, such as those intended to increase the solubility and absorption of poorly soluble medications.

IVIVC's capacity to forecast therapeutic efficacy and bioavailability without requiring comprehensive clinical research is another important use case in dosage form development. Once validated, IVIVC models enable the estimation of in vivo pharmacokinetic parameters, such as C_max (maximum plasma concentration) and AUC (area under the curve), which are essential for comprehending a drug's therapeutic profile, using in vitro dissolution data. This

https://doi.org/10.5281/zenodo.15826866

predictive ability is particularly useful for regulatory filings and early formulation screening. Developers can bypass expensive and time-consuming clinical trials when making post-approval modifications to formulations or when introducing new formulations of an existing medicine because regulatory bodies such as the FDA accept IVIVC as a foundation for biowaivers. Additionally, IVIVC helps to make the medication development process more economical and efficient by decreasing the need for in vivo investigations. This shortens time-to-market while preserving high standards of therapeutic efficacy and safety.

4.3.1 IVIVC in Formulation Optimization

Pharmaceutical formulation development benefits greatly from the use of In Vitro–In Vivo Correlation (IVIVC), particularly when it comes to optimising drug formulations that are intended to deliver medications at controlled rates, such as sustained-release (SR) and extended-release (ER) dosage forms. IVIVC predicts the in vivo pharmacokinetic behaviour (e.g., absorption rates or plasma drug concentration) based on the in vitro drug release profile. In order to maximise drug release characteristics and eventually increase the therapeutic efficacy of the treatment while reducing side effects, formulators can use this correlation to modify formulation factors [21].

Predicting the drug's release and absorption is one of IVIVC's main advantages in formulation optimisation. Formulators can estimate the drug's absorption in the human body by seeing how it performs in in vitro dissolution studies. Changes to the formulation can then be made, including changing the coating material type, excipient selection, or drug particle size. These modifications can have a major impact on the drug's release rate, ensuring that it is absorbed at the appropriate pace to sustain its therapeutic effectiveness. In a sustained-release formulation, for example, IVIVC enables formulators to customise the release profile to prevent peaks and troughs that can cause negative effects and ensure the medicine remains at therapeutic levels for a longer amount of time [22].

Improving bioavailability is a significant use of IVIVC in formulation optimisation, especially for medications that are poorly soluble. Certain medications have poor solubility, which makes it challenging for the gastrointestinal tract to properly dissolve and absorb them. IVIVC can help formulators make formulation adjustments that will increase dissolution rates and boost these medications' bioavailability. Formulators can guarantee that a sufficient amount of the

medicine enters systemic circulation to deliver the intended therapeutic effect by optimising the dissolution rate based on the correlation between in vitro data and in vivo absorption.

Additionally, IVIVC greatly lessens the requirement for in-depth in vivo research, which makes it an economical and efficient formulation development method. To evaluate a drug's in vivo performance, bioequivalence and formulation optimisation have historically needed a large number of clinical trials. Nonetheless, formulators can use in vitro dissolution data as a stand-in for in vivo testing when using a validated IVIVC model, which cuts down on the time and cost required for clinical studies. This is particularly helpful when developing new drugs or when modifying existing formulations after approval.

Additionally, IVIVC permits real-time modifications throughout the formulation development process. The IVIVC model can forecast how changes to the formulation, such as the addition of a new excipient or adjustments to the manufacturing process, will affect the drug's release and absorption characteristics. Formulators can make these forecasts with IVIVC without requiring lengthy fresh rounds of in vivo research, allowing for quicker product development schedules [23].

To sum up, IVIVC is essential to formulation optimisation because it offers a trustworthy and accurate model that links in vitro drug release to in vivo medication absorption and effectiveness. This enhances the medication's therapeutic efficacy and makes it possible to create new formulations in an economical and effective manner. IVIVC is an essential tool for the current pharmaceutical business since it can optimise drug release, improve bioavailability, decrease the requirement for in vivo investigations, and forecast the effects of formulation changes, ensuring that medications fulfil patient needs and regulatory criteria.

4.3.2 Predicting Bioavailability and Therapeutic Effect

One of the most important uses of In Vitro–In Vivo Correlation (IVIVC) in the creation of pharmacological formulations is the prediction of bioavailability and therapeutic impact. The degree and speed at which a drug or active pharmaceutical ingredient (API) is absorbed and made available at the site of action in the body is referred to as bioavailability. A medicine's therapeutic efficacy can be greatly diminished by inadequate bioavailability since some of the drug may not reach the target tissue or systemic circulation. Based on in vitro dissolution data,

https://doi.org/10.5281/zenodo.15826866

IVIVC offers a scientific foundation for forecasting and optimising a drug's bioavailability as well as its overall therapeutic performance.

When creating dosage forms with regulated or altered release profiles, including sustained-release (SR) or extended-release (ER) formulations, IVIVC is primarily used to predict bioavailability. These formulations are intended to keep therapeutic concentrations in the bloodstream for prolonged periods of time by releasing the medicine gradually over time. IVIVC helps formulators to forecast how the drug will be absorbed and how long it will be effective in the body by creating a significant association between the in vitro dissolution profile and in vivo pharmacokinetic data (such as plasma concentration-time profiles). Designing formulations that produce the intended therapeutic effects without frequent dosing—which can increase patient compliance and lessen adverse effects linked to medication peaks and troughs—requires this predictive ability [24].

Apart from formulations with continuous release, IVIVC plays a crucial role in enhancing the bioavailability of medications that are not very soluble in water. Many medications have trouble being adequately absorbed in the gastrointestinal tract, particularly those in Class II (low solubility and high permeability) or Class IV (low solubility and low permeability) of the Biopharmaceutics Classification System. A drug's bioavailability is decreased by poor solubility, which restricts how much of it dissolves and enters the bloodstream. IVIVC can assist in finding formulations that improve these poorly soluble medications' rate of dissolution, resulting in improved absorption and increased systemic bioavailability. Formulators can forecast how formulation modifications, such as the addition of solubility enhancers or new excipients, would affect the drug's bioavailability by comparing in vitro dissolution data with in vivo absorption characteristics.

A drug's bioavailability and therapeutic effect prediction are strongly related. A drug's clinical efficacy is jeopardised when it is not absorbed well, as it cannot reach therapeutic levels in the body. By forecasting how various formulations or formulation modifications would impact drug absorption, IVIVC helps to guarantee that the medication reaches its appropriate therapeutic concentration in the bloodstream [25]. A novel formulation that exhibits a faster rate of dissolution in vitro, for instance, is probably going to be absorbed more rapidly in vivo and reach therapeutic levels sooner. The medication will be taken more gradually and have a longer-lasting therapeutic impact if the dissolution is slowed. IVIVC offers a dependable

https://doi.org/10.5281/zenodo.15826866

method of forecasting the therapeutic result of a novel or altered formulation by simulating and optimising these dynamics prior to clinical trials.

Moreover, IVIVC can be utilised to forecast a drug's behaviour in diverse patient groups or physiological settings. Drugs may, for instance, have changed bioavailability in people with different metabolic rates, pH levels, or gastrointestinal issues. Formulators can predict how the medicine will behave in these populations by simulating these situations using IVIVC models. They can then modify the formulation as needed to preserve therapeutic efficacy. In personalised medicine, where therapies are customised to meet the needs of each patient, this predictive modelling can be especially helpful.

The influence of manufacturing procedures is another crucial factor in forecasting bioavailability and therapeutic effect. The rate at which the drug dissolves and, hence, its bioavailability, can be impacted by manufacturing process variability. In order to guarantee that the finished product continuously provides the required bioavailability and therapeutic impact, IVIVC allows producers to track these fluctuations and make adjustments during production. For instance, minor modifications to the excipients or coating material used in tablet formulations can have a big impact on drug release rates. IVIVC offers a mechanism to forecast these results and guarantee that these variances won't impact the medication's clinical efficacy.

In conclusion, by offering a quantifiable connection between in vitro dissolution data and in vivo pharmacokinetic results, IVIVC is an essential tool for forecasting bioavailability and therapeutic effects. Formulators can create medications with the best absorption properties, forecast their therapeutic effects, and make sure that medications retain their clinical efficacy across formulations and patient groups thanks to this prediction capabilities. Pharmaceutical companies can minimise the need for lengthy clinical trials, streamline the medication development process, and produce formulations that enhance patient outcomes and compliance by employing IVIVC to forecast bioavailability and therapeutic impact.

4.3.3 Use of IVIVC in Sustained and Controlled Release Systems

One crucial aspect of developing pharmacological formulations is the use of In Vitro–In Vivo Correlation (IVIVC) in sustained and controlled release systems. Drug formulations known as sustained release (SR) and controlled release (CR) are made to release a medication at a set

https://doi.org/10.5281/zenodo.15826866

rate over a long period of time [26]. These formulations have benefits like longer therapeutic effects, better patient compliance, and fewer side effects linked to peak plasma concentrations. Without requiring significant in vivo testing, IVIVC plays a critical role in these systems by helping to forecast the drug's behaviour in the body based on its in vitro dissolution profile. This ensures that the required release characteristics are obtained.

Establishing Predictive Correlations for Release Profiles

IVIVC is used to anticipate correlations between pharmacokinetic or in vitro drug absorption data and in vitro dissolution data. The amount of drug absorbed in vivo or the plasma concentration-time curve can be used to correlate the in vitro dissolution profile for formulations with prolonged and controlled release. Formulators can forecast the drug's therapeutic results without doing repeated human investigations by making sure that the dissolution rate in vitro corresponds to the anticipated release rate in vivo. With the help of this prediction, the release profile can be modified to achieve particular clinical goals, like maintaining a steady drug concentration over time, minimising peak-trough variations, and avoiding inadequate dosing [27].

For instance, it can be expected that a formulation that exhibits a constant and predictable dissolving pattern in vitro—such as a slow and progressive release of the active pharmaceutical ingredient—will have a smooth and controlled absorption in vivo, resulting in consistent therapeutic effects. Because of this association, formulators can improve the formulation's release properties in the laboratory, which increases the productivity and economy of sustained-release medication production.

Optimization of Drug Release Kinetics

Optimising the drug's release rate is crucial to attaining the intended therapeutic impact in the development of sustained-release and controlled-release systems. Formulators can adjust and optimise the release kinetics to match the pharmacokinetic profile required for a particular therapeutic purpose by using IVIVC. To prevent the need for several daily dosages, a controlled release formulation, for example, might be created to release the medication over the course of 24 hours, guaranteeing that therapeutic levels are maintained throughout the day.

Formulators can use IVIVC to model and modify variables such the rate at which drugs dissolve, the formulation's permeability, and the impact of excipients. The drug's release

properties can be modified to reach the desired pharmacokinetic profile after the in vitro dissolution profile and in vivo performance are closely correlated. Complex formulations, such as those made for poorly soluble medications or those that need extremely precise release rates to prevent toxicities or less-than-ideal effects, benefit greatly from this procedure [28].

Supporting Regulatory Approval and Biowaivers

Additionally advantageous for regulatory submissions is the use of IVIVC in controlled and sustained release systems, particularly when looking for biowaivers. The argument that a generic product will function similarly to the reference product can be supported by a validated IVIVC model for a sustained-release formulation, even in the absence of comprehensive in vivo bioequivalence investigations. Regulatory agencies including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) acknowledge IVIVC as a dependable method for proving therapeutic effects and release rates are equivalent, which expedites and lowers the cost of the licensing procedure.

The need for expensive and time-consuming clinical trials can be decreased, for instance, if the in vivo absorption data is closely associated with the in vitro dissolution profile of a generic controlled-release formulation, which matches that of the innovator medicine. By granting a biowaiver, regulatory bodies can expedite the product's release onto the market while maintaining therapeutic equivalency.

Predicting Clinical Performance Across Patient Populations

In the treatment of chronic diseases, when maintaining therapeutic concentrations is essential, sustained and controlled-release formulations are frequently made to deliver steady medication levels over long periods of time. IVIVC enables developers to forecast the performance of various formulations across a range of patient populations, such as individuals with varying age groups, metabolic rates, or concomitant diseases. Formulators can make sure that the sustained-release formulation will effectively treat a variety of populations by modelling the effects of physiological parameters on drug absorption and release [29].

Furthermore, in individuals with altered gastrointestinal transit durations, pH fluctuations, or diseases like diabetes or obesity that can impact drug absorption, IVIVC can assist in identifying possible problems associated to drug release. Formulators can adjust the dosage

form or release mechanism to guarantee consistent therapeutic outcomes in every patient by forecasting how the medicine will act in certain circumstances.

Enhancing Quality Control and Manufacturing Consistency

It is simpler to guarantee quality control and consistency in production if a sustained or controlled-release formulation has been created and optimised with IVIVC. Manufacturers can ensure batch-to-batch consistency by keeping an eye on each batch's in vitro dissolution profiles throughout the manufacturing process to make sure the drug's release rate stays within the intended range. This is essential for preserving the medication's therapeutic efficacy over time, particularly for medications that need extremely accurate dosage to prevent underdosing or overdose.

Early detection of possible problems in the production process is another benefit of IVIVC. Problems with product quality that could compromise patient safety can be avoided if a batch has a variation in its rate of dissolution. By lowering the expenses related to recalls, reworks, or regulatory actions, this proactive approach to quality control improves the efficiency of the manufacturing process as a whole.

4.3.4 Reducing the Need for Extensive In Vivo Studies

In order to evaluate the pharmacokinetics, safety, and effectiveness of a new medicine, in vivo studies—which usually entail testing on humans or animals—are a crucial step in the drug development process. However, when dealing with large animal populations or human participants, these investigations can be expensive, time-consuming, and ethically difficult. One major advantage in the creation of novel medications is the possibility to lessen the requirement for comprehensive in vivo research. In Vitro–In Vivo Correlation (IVIVC) is one of the best methods for achieving this reduction. IVIVC reduces the need for extra animal and human testing by enabling the prediction of in vivo drug behaviour based on in vitro dissolution data.

Predicting In Vivo Performance with In Vitro Data

IVIVC's ability to anticipate the relationship between in vitro dissolution profiles and in vivo drug absorption and pharmacokinetics is one of its main advantages. Without requiring expensive and time-consuming in vivo research, a trustworthy IVIVC model can be developed

https://doi.org/10.5281/zenodo.15826866

to mimic how a medication will act in the body. For instance, formulators can forecast a drug's pharmacokinetic profile (including C_max, AUC, and half-life) without performing in vivo trials by using the correlation between the drug's dissolution rate in vitro and its plasma concentration over time. For dose forms like extended-release (ER) or controlled-release (CR) formulations, where the release rate must be carefully regulated to guarantee constant therapeutic benefits, this predictive capability is very helpful.

Pharmaceutical developers can test different formulations and optimise release profiles early in the development process by using in vitro data to anticipate in vivo outcomes. This eliminates the need for further clinical studies to evaluate the performance of each formulation. When testing several formulations, this method is particularly helpful since it makes it possible to screen promising candidates more quickly without needing to conduct in-depth in vivo experiments for every variation.

Supporting Regulatory Decisions

Regulators including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have recognised the value of IVIVC in minimising the necessity for intensive in vivo testing. The establishment of a trustworthy IVIVC model can be utilised to support biowaivers or to request regulatory permission for novel drug formulations. For example, regulatory bodies may award a biowaiver, enabling the drug to be marketed without further in vivo bioequivalence studies, if the solubility profile of a generic formulation is similar to that of the reference drug and the in vitro data correlates well with in vivo performance. In addition to shortening the time to market, this also drastically lowers the expenses related to clinical studies, which are frequently unaffordable.

Furthermore, for some pharmacological formulations, IVIVC enables the submission of in vitro data in lieu of in vivo bioequivalence studies, particularly when those formulations show consistent and predictable release behaviours. Pharmaceutical companies might circumvent the time-consuming and resource-intensive process of performing full clinical studies in large patient cohorts by demonstrating a close relationship between a drug's in vitro dissolution pattern and its in vivo absorption properties.

Facilitating Formulation Development and Optimization

To identify the best release properties for a particular medicine, several rounds of in vivo testing are frequently required during the intricate and iterative formulation development process. Formulators can minimise the number of these rounds by employing IVIVC, which uses in vitro testing alone to predict the in vivo behaviour of different formulations. IVIVC models, for instance, can be used to evaluate various excipient combinations, doses, and release mechanisms in order to identify the formulation that would best produce the required pharmacokinetic profile. By optimising the drug's release properties more quickly, this predictive strategy lowers the need for extra in vivo trials and boosts development efficiency.

IVIVC also aids in improving drug delivery methods for medications that are challenging to synthesise, like those with limited therapeutic windows or poorly soluble compounds. However, by using in vitro dissolution data to predict the in vivo performance, formulation adjustments can be made in silico or through controlled experiments, reducing the need for extensive animal or human studies. In these situations, creating a stable drug product with controlled release can be difficult.

Ethical Considerations **and Animal Welfare**

It is also ethically acceptable to lessen the necessity for in-depth in vivo research, especially when it comes to animal welfare. The use of animals in drug testing is subject to strict laws and restrictions in many nations and regulatory bodies, which makes it necessary to minimise the use of animals whenever feasible. IVIVC offers a non-animal substitute that can reasonably predict human drug behaviour, hence reducing the need for animal testing. In tackling ethical issues in pharmaceutical research and development, this is a big step forward. Additionally, pharmaceutical corporations can improve their public image and satisfy the increasing demands of customers, regulatory agencies, and animal welfare advocacy groups by minimising animal testing and showcasing their dedication to ethical research techniques.

Cost and Time **Efficiency**

The accompanying time and expense reductions are another important benefit of IVIVC in lowering the requirement for in vivo investigations. One of the most costly and time-consuming steps in the drug development process is in vivo research, particularly clinical trials.

https://doi.org/10.5281/zenodo.15826866

In addition to the possibility of failure during the latter testing phases, these trials may take months or even years to finish. Pharmaceutical businesses can focus their resources on the most promising formulations and reduce the number of in vivo tests needed by employing IVIVC to expedite the development process. Faster market entry and more effective utilisation of research and development funding follow from this.

Additionally, IVIVC helps prevent expensive clinical trial failures by spotting possible formulation problems early in the development process. Without requiring more extensive human testing, a formulation can be modified or abandoned if it does not satisfy the intended in vivo performance standards. This is especially helpful for high-risk medications because clinical trial failure can have a significant financial impact.

4.4 SOFTWARE TOOLS FOR IVIVC PREDICTION AND OPTIMIZATION

Software technologies are now essential for forecasting and improving In Vitro–In Vivo Correlation (IVIVC) in the pharmaceutical development industry. Based on in vitro dissolution data, these software applications use sophisticated mathematical models and simulation approaches to forecast a drug's behaviour in the human body. The creation of more effective and precise drug formulations is made easier by the extensive platforms for modelling pharmacokinetics (PK) and pharmacodynamics (PD) provided by widely used IVIVC software packages like GastroPlus, Simcyp, and WinNonlin. For instance, GastroPlus is well known for its capacity to model ADME (absorption, distribution, metabolism, and excretion) processes, offering valuable information on how modifications to formulation factors (such as excipients or particle size) impact drug bioavailability. Another popular tool for population-based simulations is Simcyp, which enables researchers to mimic drug use across various demographic groups and forecast the effects of physiological variations. Conversely, WinNonlin is a mainstay of non-compartmental pharmacokinetic analysis and provides instruments for assessing drug concentration-time profiles, which makes it appropriate for both advanced and early-stage IVIVC modelling.

The main benefit of utilising these software solutions is their wealth of features and functionalities. These algorithms make it easier to anticipate treatment outcomes by simulating drug absorption and bioavailability as well as integrating different formulations, dissolution rates, and drug release profiles. For example, they can assist in simulating the relationship between alterations in a drug's in vitro dissolution profile and its in vivo plasma concentration

https://doi.org/10.5281/zenodo.15826866

and bioavailability. Researchers can adjust formulation parameters to achieve desired therapeutic results while minimising toxicity or adverse effects because to the software's frequent inclusion of optimisation algorithms. Furthermore, because they offer data-driven models that might bolster claims for biowaivers or bioequivalence, these tools are crucial in regulatory submissions. Since software-based IVIVC predictions offer a reliable and scientifically verified method for evaluating the pharmacokinetic behaviour of medicinal items, regulatory bodies such as the FDA and EMA have really begun to embrace them more and more in the approval process. As a result, IVIVC software solutions improve overall drug development accuracy and efficiency while also streamlining the formulation development process and adhering to regulatory standards.

4.4.1 Overview of Commonly Used IVIVC Software (e.g., GastroPlus, Simcyp, WinNonlin)

The development of modern software tools that allow for drug formulation simulation, prediction, and optimisation has led to a considerable advancement in in vitro–in vivo correlation (IVIVC) modelling. With unique capabilities catered to different facets of IVIVC modelling, GastroPlus, Simcyp, and WinNonlin are some of the most widely used software systems in pharmaceutical research and development.

The software GastroPlus mimics the oral absorption, distribution, metabolism, and excretion (ADME) of medications in the human body using physiologically based pharmacokinetic (PBPK) modelling. One of the most sophisticated methods for forecasting in vivo results from in vitro dissolution data was created by Simulations Plus. GastroPlus makes it possible to model drug behaviour in the gastrointestinal (GI) tract in great detail, accounting for a number of physiological variables like pH, transit time, and enzyme activity. It is a well-liked option for IVIVC development and optimisation because of its integrated modules, such as the Advanced Compartmental Absorption and Transit (ACAT) model, which are especially helpful for simulating controlled-release and immediate-release formulations.

https://doi.org/10.5281/zenodo.15826866

Figure 2: GastroPlus

Certara's Simcyp Simulator is a popular tool for population-based pharmacokinetic simulations. It is intended to simulate the absorption and metabolism of medications in a variety of demographics, such as age groups, ethnic groupings, and people with certain medical conditions. By incorporating physiological variability into IVIVC models, Simcyp provides a prediction framework that takes into account both inter-individual variations and pharmacological characteristics. Particularly in later stages of clinical development, this software is useful for evaluating bioavailability, possible drug-drug interactions, and dose modifications.

One of the best tools for analysing pharmacokinetic (PK) and pharmacodynamic (PD) data is WinNonlin, which Certara also developed. In regulatory submissions, it is frequently used to develop IVIVC connections and supports both compartmental and non-compartmental modelling. With WinNonlin's intuitive interface for statistical analysis, parameter estimation, and data fitting, researchers may quickly create Level A, B, or C correlations. It is especially preferred for its ease of use in bioequivalence and early-stage drug development.

The foundation of contemporary IVIVC modelling is made up of several software tools, which enable pharmaceutical scientists to optimise formulation parameters, simulate drug efficacy, and lessen the need for in-depth in vivo research. Their incorporation into regulatory

frameworks highlights their significance in guaranteeing drug development that is safe, efficient, and economical.

4.4.2 Features and Capabilities of IVIVC Software

1. Physiologically Based Pharmacokinetic (PBPK) Modeling

Physiologically Based Pharmacokinetic (PBPK) modelling is essential for creating in vitro–in vivo correlations (IVIVC), especially when using specialised software like Simcyp and GastroPlus. To estimate the absorption, distribution, metabolism, and excretion (ADME) of a drug in the human or animal body, these sophisticated computer tools employ PBPK models. PBPK modeling's strength is its capacity to include intricate physiological and biochemical processes into a logical framework that closely resembles real biological systems. With merely in vitro dissolution or formulation data as a starting point, it becomes a powerful tool for forecasting how a medication would behave in vivo.



Figure 3: PBPK Model

The gastrointestinal tract's physiological conditions, such as pH gradients, enzyme activity, regional permeability, and gastric emptying times, are replicated by PBPK software, which offers incredibly detailed simulations that are not achievable with conventional empirical

https://doi.org/10.5281/zenodo.15826866

models. To track how a drug dissolves, precipitates, or absorbs at various segments of the GI tract, GastroPlus, for instance, uses the Advanced Compartmental Absorption and Transit (ACAT) model. With Simcyp, however, researchers may assess inter-individual variability in medication response through population-based simulations. During medication development, this kind of thorough modelling not only helps create reliable IVIVCs but also lessens the need for intensive human or animal testing. In the end, PBPK modelling is an effective technique that aids in well-informed choices for formulation optimisation and regulatory filings.

2. Advanced Compartmental and Non-Compartmental Modeling

A key component of IVIVC development is advanced compartmental and non-compartmental modelling, and the pharmaceutical industry frequently uses tools like WinNonlin for this. Researchers can conduct compartmental and non-compartmental analysis (NCA) using WinNonlin's versatile platform, which is based on a drug's pharmacokinetic (PK) profile. This dual feature is very useful since it allows researchers to select the best modelling method based on the intricacy of the drug's ADME (absorption, distribution, metabolism, and excretion) properties.

Compartmental models depict the drug's gradual distribution throughout the body as a network of interconnected compartments. By offering a point-to-point correlation between in vitro dissolution data and in vivo plasma concentration profiles, these models enable the detailed construction of Level A IVIVC, making them perfect for medications with complex PK behaviour, particularly in the case of extended-release or sustained-release formulations. However, non-compartmental models, which are grounded on statistical moment theory, are more straightforward. They are frequently employed for preliminary analysis or in situations where there is not enough data for complete compartmental modelling. Despite lacking the depth of mechanistic understanding that compartmental modelling offers, NCA is useful for determining important PK parameters that are necessary for IVIVC evaluation, such as AUC (Area Under the Curve), Cmax, and Tmax. WinNonlin is a vital tool in both development and regulatory contexts because of its capacity to carry out both kinds of analysis, which increases its usefulness for modelling a variety of drug compositions.

https://doi.org/10.5281/zenodo.15826866

3. Simulation of Multiple Dosage Forms

One of the most potent features of sophisticated IVIVC software programs like GastroPlus, Simcyp, and WinNonlin is the ability to simulate many dosage forms. Pharmaceutical scientists can use these tools to model and simulate different kinds of drug delivery systems, such as formulations that are controlled-release (CR), sustained-release (SR), and immediate-release (IR). Understanding how various release mechanisms impact medication absorption and bioavailability is essential for therapeutic effectiveness, and this capability is especially helpful in formulation creation.

Before starting real in vivo studies, researchers can use these software platforms to evaluate and compare various formulation processes realistically under physiologically simulated conditions. This simulation aids in forecasting a formulation's dissolution, absorption rate, and plasma concentration-time profile in the gastrointestinal (GI) tract. Formulation scientists can fine-tune excipient selection, drug coating thickness, and matrix composition by modelling different release patterns. This ensures that the medicine gets the desired therapeutic effect with the least amount of trial and error. Because of this, simulation not only makes the medication development process more efficient, but it also drastically cuts down on the time and expense of conventional formulation testing and bioavailability studies. By creating trustworthy IVIVC models, this predictive ability aids in the logical design and optimisation of dosage forms and can play a key role in obtaining regulatory approvals.

4. Optimization of Formulation Parameters

One of the most useful features provided by IVIVC (In Vitro-In Vivo Correlation) software programs like GastroPlus, Simcyp, and WinNonlin is the optimisation of formulation parameters. The sensitivity analysis and parameter optimisation modules that are included into these tools are essential for determining and adjusting the key factors that affect drug release, absorption, and general pharmacokinetic behaviour. The software enables researchers to methodically evaluate how modifications to formulation elements—like polymer type, granule size, coating thickness, or dissolution rate—affect a drug's in vivo performance using simulation models and computer algorithms.

The software determines which formulation factors have the biggest effects on important pharmacokinetic metrics such as C_max (maximum concentration), T_max (time to reach

https://doi.org/10.5281/zenodo.15826866

C_max), and AUC (area under the curve) by enabling sensitivity analysis. After that, these variables might be changed in silico using optimisation tools to satisfy certain therapeutic goals or legal specifications. Compared to conventional laboratory trial-and-error techniques, this iterative refinement procedure saves time and money. Additionally, it improves the capacity to create reliable, repeatable dose forms with steady bioavailability. All things considered, IVIVC software's optimisation capabilities expedite the formulation creation process and are essential to guaranteeing that the medication product successfully and efficiently achieves its targeted therapeutic goals.

5. Integration with Experimental Data

A key component of contemporary IVIVC (In Vitro-In Vivo Correlation) software solutions like GastroPlus, Simcyp, and WinNonlin is integration with experimental data. These systems are made to easily integrate in vivo pharmacokinetic (PK) and experimental in vitro dissolution data into their modelling workflows. These methods aid in bridging the gap between empirical observations and predictive modelling by embracing real-time lab-generated data, guaranteeing that the simulations accurately depict biological behaviour. Through this integration, researchers can enter dissolution profiles that were acquired in a variety of settings (such as different media, pH levels, or formulation types) and compare them to real pharmacokinetic results like bioavailability, therapeutic effect, and plasma concentration-time profiles.

The software allows users to do data fitting and model validation after the experimental data is fed into the system. These tasks are crucial for creating dependable and legally acceptable IVIVC models. The software's sophisticated statistical algorithms evaluate prediction accuracy, residual errors, and goodness-of-fit, validating the robustness and consistency of the found association. The software can also do predictive tests, which compare the outcomes with real observations and use in vitro data to forecast in vivo performance. By doing this, the IVIVC model is guaranteed to be both descriptive and predictive. These techniques significantly improve formulation development and regulatory submissions' efficiency, correctness, and credibility by fusing empirical data with strong mathematical modelling.

6. Regulatory Reporting and Compliance

IVIVC (In Vitro-In Vivo Correlation) software plays a crucial role in regulatory reporting and compliance, particularly when it comes to the procedures of drug development and approval.

https://doi.org/10.5281/zenodo.15826866

GastroPlus, Simcyp, and WinNonlin are examples of advanced IVIVC tools that are specifically made to produce regulatory-compliant outputs that satisfy the strict documentation requirements set by regulatory bodies such as the European Medicines Agency (EMA), the Central Drugs Standard Control Organisation (CDSCO), and the U.S. Food and Drug Administration (FDA). In-depth reports including statistical analysis, summaries of pharmacokinetic and pharmacodynamic modelling, dissolution profiles, simulation findings, and graphical representations such residual plots and plasma concentration-time curves are among these outputs.

These software programs guarantee that the documentation style, analysis methods, and data formats meet international regulatory requirements. The time needed for regulatory preparation is greatly decreased and the possibility of human error is decreased by the capacity to automatically generate standardised templates and datasets. These tools also facilitate the creation of electronic submission files that are compatible with regulatory portals, facilitating requests for biowaivers, which enable businesses to avoid costly and time-consuming in vivo bioequivalence studies based on strong IVIVC evidence. This ensures smooth communication. These findings can also support the similarity in medication performance, which helps pharmaceutical companies justify that the amended formulation is still therapeutically equivalent when they seek clearance for post-approved formulation adjustments. Therefore, IVIVC software's regulatory compliance features are essential for speeding up drug development without sacrificing quality or regulatory integrity.

7. Visualization and Data Interpretation Tools

Essential components of IVIVC (In Vitro-In Vivo Correlation) software are visualisation and data interpretation tools, which give users clear graphical outputs that significantly improve comprehension of intricate pharmacokinetic data. The majority of contemporary IVIVC platforms, including WinNonlin, Simcyp, and GastroPlus, provide a variety of sophisticated graphical tools intended to illustrate the connection between in vivo drug performance and in vitro dissolution profiles. In order to evaluate and validate the outcomes of simulations and experimental data, these graphical outputs usually consist of dissolution curves, plasma concentration-time profiles, bioavailability plots, and model validation charts.

Researchers can easily and directly discover any differences or areas where the model may need to be improved by using these graphical tools to visually compare the in vitro dissolution

data with the in vivo pharmacokinetic data. For instance, the drug's absorption, distribution, metabolism, and excretion (ADME) activities in the body are shown over time using plasma concentration-time curves. Investigators can rapidly determine whether the formulation acts as anticipated in a biological system by comparing these curves from in vitro dissolution data and in vivo simulations. Furthermore, by contrasting simulated outcomes with actual data, model validation plots assist in verifying the IVIVC model's resilience. Making better decisions is made possible by this visual depiction, which helps identify any errors in the model or the experimental setup.

Furthermore, these technologies' sophisticated visualisation features aid in promoting communication amongst pharmaceutical businesses' interdisciplinary teams, such as regulatory affairs teams, pharmacokinetic specialists, and formulation scientists. Team members can swiftly understand the ramifications of their findings, exchange ideas, and work together to optimise formulations or regulatory strategies when complex data is presented in an understandable graphical style. These technologies facilitate decision-making by making data interpretation easier to understand, enabling businesses to proceed with medication development and regulatory submissions more quickly.

8. Virtual Trials and Population Simulations

Advanced IVIVC software tools like Simcyp offer powerful features like virtual trials and population simulations that allow the simulation of drug behaviour across various patient populations. These simulations provide important insights into how different demographic variables, including age, weight, and genetics, can affect drug absorption, distribution, metabolism, and excretion (ADME). Researchers can save time, money, and resources by simulating clinical circumstances using these virtual trials instead of real human trials. Drug developers can evaluate drug response variability and enhance clinical study design by using population simulations to forecast how a drug will behave in various population segments.

The capacity to take into consideration inter-individual variability in medication response—which can be impacted by a variety of factors such as genetic variations, body weight, age, sex, lifestyle factors, and underlying medical conditions—is one of the main advantages of computer simulations. For instance, genetic variations may change the toxicity or efficacy of medications, or older populations may metabolise drugs differently than younger ones. Researchers can improve the safety and effectiveness of the medication across various patient

https://doi.org/10.5281/zenodo.15826866

populations by employing population simulations to detect these variations early in the development process and adjust dose schedules accordingly.

The expanding discipline of personalised medicine, in which medication treatments are customised for each patient according to their distinct genetic and demographic traits, is also supported by these tools. Virtual trials can assist in creating patient-specific treatment strategies that optimise therapeutic outcomes while minimising side effects by forecasting how various populations would react to a medication. Before clinical trials are carried out, researchers can better understand and reduce potential dangers by using these models to evaluate risk variables for certain populations. A drug's approval process can be greatly bolstered by showcasing a thorough understanding of population heterogeneity in regulatory submissions, especially when providing evidence for labelling recommendations and dosing guidelines.

4.4.3 Case Studies: Software-Based IVIVC in Drug Development

Drug development has benefited greatly from software-based IVIVC (in vitro–in vivo correlation) modelling, which provides a more effective, economical, and predictive method of evaluating the bioavailability and therapeutic efficacy of drugs. Several case studies show how sophisticated software programs such as GastroPlus, Simcyp, and WinNonlin can effectively simulate pharmacological behaviour, optimise formulations, and support regulatory decisions. These case studies demonstrate how IVIVC software may be used practically in actual drug development situations, highlighting how predictive modelling can expedite the release of novel medications.

The creation of sustained-release formulations is one noteworthy case study in which the in vivo drug release profile was predicted using in vitro dissolution data using software-based IVIVC modelling. For example, before doing expensive and time-consuming in vivo clinical trials, a pharmaceutical company used GastroPlus to model the pharmacokinetic behaviour of a sustained-release version of a medicine. The software simulated the drug's release from the dosage form while accounting for the pH, enzyme activity in various GI tract segments, and gastrointestinal transit time. The plasma concentration-time curve was accurately predicted by the generated simulation, and it closely matched the real in vivo data from further clinical studies. As a result, fewer comprehensive animal and human experiments were required, and the company was able to optimise the formulation and expedite the approval procedure.

Simcyp was also used to mimic medication responses specific to a population, especially in a variety of demographic groups. Simcyp's population simulation features were utilised by a pharmaceutical business creating a medication for chronic pain to forecast how the medication will act across various age groups, ethnicities, and genetic profiles. This made it possible for the business to detect any possible problems with variations in drug metabolism or absorption prior to clinical testing. For instance, the simulation showed that senior patients would metabolise the medicine more slowly. As a result, the dosage schedule was modified for this demographic to guarantee effectiveness and reduce adverse effects. These results were crucial during the clinical trial stage since they made it possible to recruit people more precisely and decreased the possibility of unfavourable results.

The adaptability and strength of software-based IVIVC in drug development are demonstrated by these case studies. These technologies aid in formulation optimisation, patient safety, and development schedule reduction by allowing researchers to model a variety of scenarios. They also offer a strong framework for regulatory submissions, including predictive data to support requests for biowaivers and aid in proving the clinical equivalency of generic formulations. Pharmaceutical firms can guarantee improved drug performance and more effective regulatory navigation, which lowers expenses and increases the chances of clinical trial success, by using such software.

4.4.4. Integration of Software in Regulatory Submissions

Since software-based IVIVC models provide a quick and scientifically sound way to support therapeutic equivalence, bioequivalence, and formulation optimisation, their incorporation into regulatory submissions has become a crucial part of contemporary drug development. Software tools like GastroPlus, Simcyp, and WinNonlin are valued by regulatory bodies including the FDA, EMA, and CDSCO because they can forecast in vivo drug behaviour from in vitro data. The regulatory process will be greatly impacted by this prediction power, particularly when conventional in vivo bioequivalence investigations are expensive, time-consuming, or morally difficult.

Software-based IVIVC models offer a practical means of proving in regulatory submissions that a novel drug formulation exhibits comparable pharmacokinetics, therapeutic efficacy, and absorption profile to a reference medication. Pharmaceutical firms can use these models to produce simulation results that forecast the cumulative medication absorbed over time or the

https://doi.org/10.5281/zenodo.15826866

plasma concentration-time curve based on in vitro dissolution profiles. Without requiring in-depth in vivo research, it is feasible to demonstrate that a novel formulation is bioequivalent to an existing medication when these simulations agree with observed in vivo data. By simulating the effects of various formulations or manufacturing procedures on drug release, for instance, GastroPlus enables businesses to optimise formulations early in the development process and guarantees that regulatory bodies may examine data that represents the most reliable and accurate forecasts. Clinical trials are also less burdened by the possibility to include IVIVC software into the regulatory submission procedure. Before clinical testing, these software tools can model the in vivo effect of formulation modifications that a corporation wants to make, such as changing the dosage form from immediate-release to controlled-release. These software-based simulations can be accepted by regulatory agencies as part of the submission package, particularly if they are supported by pertinent pharmacokinetic and in vitro data. Pharmaceutical firms may be eligible for biowaivers, in which clinical trials are not necessary for the licensing of generic medications, by submitting software-predicted data. This would further expedite the time to market and lower related expenses.

Furthermore, model-based methods are becoming more and more necessary for regulatory bodies to prove the safety, effectiveness, and bioequivalence of complicated formulations. These needs are met by WinNonlin and Simcyp, which make it possible to integrate sensitivity studies and population-level simulations. By modelling different patient groups, such as those with certain genetic variants or comorbidities, these technologies can shed light on how medication formulations may function in a range of demographics. This degree of specificity helps meet regulatory requirements for comprehensive risk evaluations and safety profiles and supports personalised medicine initiatives, especially for medications with complex pharmacokinetic behaviours or those targeted at specialised therapeutic areas.

All things considered, it is becoming more widely acknowledged that incorporating IVIVC software into regulatory submissions is an essential tool for effective drug development. Pharmaceutical companies can show that their formulations are safe and effective by giving regulators predictive, data-driven insights into a drug's behaviour. This can eliminate the need for extensive clinical studies and possibly expedite the licensing process. This in turn facilitates the quick launch of superior, therapeutically equivalent generics, allowing more patients to obtain necessary drugs.

REFERENCES

1. Kraus, M., Müller-Ide, H., Rückrich, T., Bader, J., Overkleeft, H., & Driessen, C. (2014). Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. *Leukemia research*, *38*(3), 383-392.
2. Kumar, D. D., Ancheria, R., Shrivastava, S., Soni, S. L., & Sharma, M. (2019). Review on pharmaceutical quality by design (QbD). *Asian Journal of Pharmaceutical Research and Development*, *7*(2), 78-82.
3. L. Mallipeddi, P., Kumar, G., W. White, S., & R. Webb, T. (2014). Recent advances in computer-aided drug design as applied to anti-influenza drug discovery. *Current Topics in Medicinal Chemistry*, *14*(16), 1875-1889.
4. Laeeq, S., Sirbaiya, A. K., Siddiqui, H. H., & Zaidi, S. M. H. (2014). An overview of the computer aided drug designing. *Int. J. Pharm. Pharm. Sci*, *3*, 963-994.
5. Lai, X., Geier, O. M., Fleischer, T., Garred, Ø., Borgen, E., Funke, S. W., ... & Frigessi, A. (2019). Toward personalized computer simulation of breast cancer treatment: A multiscale pharmacokinetic and pharmacodynamic model informed by multitype patient data. *Cancer research*, *79*(16), 4293-4304.
6. Lee, J. W., Maria-Solano, M. A., Vu, T. N. L., Yoon, S., & Choi, S. (2022). Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD). *Biochemical Society Transactions*, *50*(1), 241-252.
7. Lee, S. H., Kim, J. K., Jee, J. P., Jang, D. J., Park, Y. J., & Kim, J. E. (2022). Quality by Design (QbD) application for the pharmaceutical development process. *Journal of Pharmaceutical Investigation*, *52*(6), 649-682.
8. Leelananda, S. P., & Lindert, S. (2016). Computational methods in drug discovery. *Beilstein journal of organic chemistry*, *12*(1), 2694-2718.
9. Lejniece, S., Udre, I., & Rivkina, A. (2017). Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia. *Experimental Oncology*.
10. Lill, M. A., & Danielson, M. L. (2011). Computer-aided drug design platform using PyMOL. *Journal of computer-aided molecular design*, *25*, 13-19.

11. Liu, Y., Gan, J., Wang, R., Yang, X., Xiao, Z., & Cao, Y. (2022). DrugDevCovid19: An atlas of anti-COVID-19 compounds derived by computer-aided drug design. *Molecules*, *27*(3), 683.
12. Llorach-Pares, L., Nonell-Canals, A., Sanchez-Martinez, M., & Avila, C. (2017). Computer-aided drug design applied to marine drug discovery: Meridianins as Alzheimer's disease therapeutic agents. *Marine drugs*, *15*(12), 366.
13. Lv, Z., Chu, Y., & Wang, Y. (2015). HIV protease inhibitors: a review of molecular selectivity and toxicity. *HIV/AIDS-Research and palliative care*, 95-104.
14. Macalino, S. J. Y., Gosu, V., Hong, S., & Choi, S. (2015). Role of computer-aided drug design in modern drug discovery. *Archives of pharmacal research*, *38*, 1686-1701.
15. Mahdi, M., Mótyán, J. A., Szojka, Z. I., Golda, M., Miczi, M., & Tőzsér, J. (2020). Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′ s main protease. *Virology journal*, *17*, 1-8.
16. Maksimovic-Ivanic, D., Fagone, P., McCubrey, J., Bendtzen, K., Mijatovic, S., & Nicoletti, F. (2017). HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. *International journal of cancer*, *140*(8), 1713-1726.
17. Marin, R. C., Behl, T., Negrut, N., & Bungau, S. (2021). Management of antiretroviral therapy with boosted protease inhibitors—darunavir/ritonavir or darunavir/cobicistat. *Biomedicines*, *9*(3), 313.
18. Mathivanan, J. S., Dhayabaran, V. V., David, M. R., Karuna Nidhi, M. B., Prasath, K. M., & Suvaithenamudhan, S. (2024). Application of Deep Learning Neural Networks in Computer-Aided Drug Discovery: A Review. *Current Bioinformatics*, *19*(9), 851-858.
19. Mishra, T. D., Kurani, H., Singhal, P., & Shrivastav, P. S. (2012). Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC–ESI-MS-MS. *Journal of chromatographic science*, *50*(7), 625-635.
20. Mishra, V., Thakur, S., Patil, A., & Shukla, A. (2018). Quality by design (QbD) approaches in current pharmaceutical set-up. *Expert opinion on drug delivery*, *15*(8), 737-758.

21. Mittal, P., Chopra, H., Kaur, K. P., & Gautam, R. K. (2023). New drug discovery pipeline. In *Computational Approaches in Drug Discovery, Development and Systems Pharmacology* (pp. 197-222). Academic Press.
22. Mohammed, K. (2013). Possible adverse cutaneous effects in patients taking imatinib mesylate (Gleevec) in treatment of chronic myeloid leukemia (CML) and gastro intestinal stromal tumors (GISTs) at Hilla City. *Medical Journal of Babylon*, *10*(3).
23. Mohurle, M. S. M., Asnani, M. D. A. J., Chaple, D. R., Kurian, M. J., & Bais, M. A. G. (2019). Quality by Design (QbD): an emerging trend in improving quality & development of pharmaceuticals. *Saudi J Med Pharm Sci*, *5*(12), 1132-8.
24. Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2021, January). Computer-aided drug repurposing for cancer therapy: approaches and opportChapteries to challenge anticancer targets. In *Seminars in cancer biology* (Vol. 68, pp. 59-74). Academic Press.
25. Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., ... & Tropsha, A. (2021). A critical overview of computational approaches employed for COVID-19 drug discovery. *Chemical Society Reviews*, *50*(16), 9121-9151.
26. Nascimento, A. L., Fernandes, R. P., Quijia, C., Araujo, V. H., Pereira, J., Garcia, J. S., ... & Chorilli, M. (2020). Pharmacokinetic parameters of HIV-1 protease inhibitors. *ChemMedChem*, *15*(12), 1018-1029.
27. Nascimento, I. J. D. S., de Aquino, T. M., & da Silva-Júnior, E. F. (2022). The new era of drug discovery: The power of computer-aided drug design (CADD). *Letters in Drug Design & Discovery*, *19*(11), 951-955.
28. Nascimento, I. J. D. S., de Aquino, T. M., & da Silva-Júnior, E. F. (2022). The new era of drug discovery: The power of computer-aided drug design (CADD). *Letters in Drug Design & Discovery*, *19*(11), 951-955.
29. Nayak, A. K., Ahmed, S. A., Beg, S., Tabish, M., & Hasnain, M. S. (2019). Application of quality by design for the development of biopharmaceuticals. In *Pharmaceutical quality by design* (pp. 399-411). Academic Press.